Compare JFIN & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JFIN | MYO |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.0M | 63.8M |
| IPO Year | 2018 | 2017 |
| Metric | JFIN | MYO |
|---|---|---|
| Price | $1.31 | $1.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.64 |
| AVG Volume (30 Days) | 34.9K | ★ 245.1K |
| Earning Date | 11-24-2026 | 11-09-2026 |
| Dividend Yield | ★ 61.78% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000,000.00 |
| Revenue This Year | N/A | $11.43 |
| Revenue Next Year | N/A | $12.29 |
| P/E Ratio | $1.35 | ★ N/A |
| Revenue Growth | N/A | ★ 40814.79 |
| 52 Week Low | $1.13 | $0.61 |
| 52 Week High | $10.06 | $1.89 |
| Indicator | JFIN | MYO |
|---|---|---|
| Relative Strength Index (RSI) | 40.83 | 37.46 |
| Support Level | $1.26 | $1.18 |
| Resistance Level | $1.62 | $1.75 |
| Average True Range (ATR) | 0.11 | 0.10 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 50.00 | 11.90 |
Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.